<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3113">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623619</url>
  </required_header>
  <id_info>
    <org_study_id>20201109</org_study_id>
    <nct_id>NCT04623619</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Acetyl L-Carnitine in COVID-19 Patients With Mild-to-Moderate Disease</brief_title>
  <official_title>Use of Acetyl L-Carnitine in Patients With Covid-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Different studies showed that acetyl L-Carnitine (LC) positively affects the development and&#xD;
      maturation of T lymphocytes, involved in the immune response to viral agents. It also&#xD;
      contributes to the inhibition of ROS production and to the remodulation of the cytokine&#xD;
      network typical of the systemic inflammatory syndrome.&#xD;
&#xD;
      Given the potential protective effects of LC, it is suggested as a supportive and therapeutic&#xD;
      option in patients with coronavirus infection. Given this background, in the light of the&#xD;
      current COVID-19 emergency, it is the intention of the investigators to conduct a&#xD;
      prospective, randomized, open-label, controlled study in the cohort of hospitalized patients&#xD;
      with covid-19 pneumonia, administering 2 gr of LC orally in addition to the standard of care&#xD;
      therapy (SOC).&#xD;
&#xD;
      The investigators hypothesize that the use of LC will be associated with an earlier&#xD;
      improvement of clinical and biohumoral parameters after 14 days of LC treatment when compared&#xD;
      to the group of patients provided with standard care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Different studies showed that acetyl L-Carnitine (LC) positively affects the development and&#xD;
      maturation of T lymphocytes, involved in the immune response to viral agents. It also&#xD;
      contributes to the inhibition of ROS production and to the remodulation of the cytokine&#xD;
      network typical of the systemic inflammatory syndrome.&#xD;
&#xD;
      SARS-CoV-2 virus activates the human cell ACE2 receptor, triggering a series of deleterious&#xD;
      events. In COVID19, renin-angiotensin is upregulated and the pathway is overexpressed and a&#xD;
      progressive cytokine storm is always observed. In all these pathogenic processes, LC could&#xD;
      play a modifier function to enhance condition. LC can be beneficial to the antioxidant&#xD;
      effects of Angiotensin II by inhibiting NF-kB and down-regulating NOX1and NOX2. For LC, an&#xD;
      anti-apoptotic and genome-stabilizer role was estimated by inhibiting pro-apoptotic caspases&#xD;
      and activating PARP-1. LC is an immunomodulator that downregulates pro-inflammatory cytokines&#xD;
      including TNF-α, IL-6, and IL-1 that could extinguish the cytokine storm. LC can also serve&#xD;
      as a protective agent against COVID19 cardiotoxicity due to disruption in the ACE2-mediated&#xD;
      signaling pathway, cytokine storm, pulmonary dysfunction, and side effects of medications.&#xD;
&#xD;
      In patients with coronavirus infection, provided LC's possible protective effects, it is&#xD;
      suggested as a supportive and therapeutic alternative.&#xD;
&#xD;
      Given this background, in the light of the current COVID-19 emergency, it is the intention of&#xD;
      the investigators to conduct a prospective, randomized, open-label, controlled study in the&#xD;
      cohort of hospitalized patients with covid-19 pneumonia, administering 2 gr of LC orally in&#xD;
      addition to the standard of care therapy (SOC).&#xD;
&#xD;
      The investigators hypothesize that the use of LC will be associated with an earlier&#xD;
      improvement of clinical and humoral parameters after 14 days of LC treatment when compared to&#xD;
      the group of patients provided with standard care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, open-label, controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>72 hours</time_frame>
    <description>Change of hospital mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C reactive protein (CRP) levels</measure>
    <time_frame>72 hours</time_frame>
    <description>Reduction of CRP levels &gt; 50% in comparison with CRP levels at the admission, within 72 hours after the administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 levels</measure>
    <time_frame>72 hours</time_frame>
    <description>Reduction of IL-6 levels &gt; 50% in comparison with IL-6 at the admission, within 72 hours after the administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer levels</measure>
    <time_frame>72 hours</time_frame>
    <description>Reduction of D-dimer levels &gt; 50% in comparison with D-dimer at the admission, within 72 hours after the administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of positive PCR swab</measure>
    <time_frame>5 days</time_frame>
    <description>Time length of negativization of PCR molecular swab</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Acetyl L-Carnitine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetyl L-Carnitine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Acetyl L-Carnitine</intervention_name>
    <description>Administering 2 gr of Acetyl L-Carnitine orally in addition to the standard of care therapy for 14 days</description>
    <arm_group_label>Acetyl L-Carnitine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive swab test of SARS-CoV-2&#xD;
&#xD;
          -  Pneumonia related to SARS-CoV-2&#xD;
&#xD;
          -  Signature of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unsigned informed consent&#xD;
&#xD;
          -  Negative swab test of SARS-CoV-2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Cascio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Palermo, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Cascio, MD, PhD</last_name>
    <phone>3389912198</phone>
    <email>antonio.cascio03@unipa.it</email>
  </overall_contact>
  <reference>
    <citation>Blanca AJ, Ruiz-Armenta MV, Zambrano S, Miguel-Carrasco JL, González-Roncero FM, Fortuño A, Revilla E, Mate A, Vázquez CM. l-Carnitine ameliorates the oxidative stress response to angiotensin II by modulating NADPH oxidase through a reduction in protein kinase c activity and NF-κB translocation to the nucleus. Food Chem. 2017 Aug 1;228:356-366. doi: 10.1016/j.foodchem.2017.02.011. Epub 2017 Feb 6.</citation>
    <PMID>28317735</PMID>
  </reference>
  <reference>
    <citation>Puskarich MA, Kline JA, Krabill V, Claremont H, Jones AE. Preliminary safety and efficacy of L-carnitine infusion for the treatment of vasopressor-dependent septic shock: a randomized control trial. JPEN J Parenter Enteral Nutr. 2014 Aug;38(6):736-43. doi: 10.1177/0148607113495414. Epub 2013 Jul 12.</citation>
    <PMID>23851424</PMID>
  </reference>
  <reference>
    <citation>Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, Chen L, Li M, Liu Y, Wang G, Yuan Z, Feng Z, Zhang Y, Wu Y, Chen Y. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020 May 1;11:827. doi: 10.3389/fimmu.2020.00827. eCollection 2020.</citation>
    <PMID>32425950</PMID>
  </reference>
  <reference>
    <citation>Moretti S, Alesse E, Di Marzio L, Zazzeroni F, Ruggeri B, Marcellini S, Famularo G, Steinberg SM, Boschini A, Cifone MG, De Simone C. Effect of L-carnitine on human immunodeficiency virus-1 infection-associated apoptosis: a pilot study. Blood. 1998 May 15;91(10):3817-24.</citation>
    <PMID>9573019</PMID>
  </reference>
  <reference>
    <citation>Wang ZY, Liu YY, Liu GH, Lu HB, Mao CY. l-Carnitine and heart disease. Life Sci. 2018 Feb 1;194:88-97. doi: 10.1016/j.lfs.2017.12.015. Epub 2017 Dec 11. Review.</citation>
    <PMID>29241711</PMID>
  </reference>
  <reference>
    <citation>Mohammadi M, Hajhossein Talasaz A, Alidoosti M. Preventive effect of l-carnitine and its derivatives on endothelial dysfunction and platelet aggregation. Clin Nutr ESPEN. 2016 Oct;15:1-10. doi: 10.1016/j.clnesp.2016.06.009. Epub 2016 Jun 27. Review.</citation>
    <PMID>28531771</PMID>
  </reference>
  <reference>
    <citation>Görlinger K, Dirkmann D, Gandhi A, Simioni P. COVID-19-Associated Coagulopathy and Inflammatory Response: What Do We Know Already and What Are the Knowledge Gaps? Anesth Analg. 2020 Nov;131(5):1324-1333. doi: 10.1213/ANE.0000000000005147. Review.</citation>
    <PMID>33079850</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 15, 2020</last_update_submitted>
  <last_update_submitted_qc>November 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo</investigator_affiliation>
    <investigator_full_name>Antonio Cascio</investigator_full_name>
    <investigator_title>Direttore UOC Malattie Infettive e Tropicali</investigator_title>
  </responsible_party>
  <keyword>acetyl L-Carnitine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcarnitine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

